Todd Kremin

From:

Robert Trumpy

Sent:

Thursday, June 15, 2006 11:26 AM

To:

'mcs@barronpartners.com'

Cc:

Henry Warner

Subject:

Biosafe conference call

Attachments: Retail proforma 06-14-06.xls

Matt, here are the revised projections with our best assumptions/data. Since several of your people are on vacation next week could we have a status conf call on Friday AM?

Rob Trumpy, CPA SVP and CFO BioSafe Medical Technologies, Inc. 100 Field Drive, Suite 240 Lake Forest, IL 60045 Work:847-234-8111 Fax:847-234-8222 rtrumpy@ebiosafe.com

% of Revenue Confidential	Income Taxes	Pre Tax Profit (Loss)	Interest Income	EBIT % of Revenue	Depreciation and Amortization	% of Revenue	FRITDA Total S,G & A	Travel & Entertainment	Advertising/Marketing 4%	Other Expenses	General Insurance	Professional	Payroll Tax & Benefits	Other Salaries	Sales and Commissions 2%	Selling, General and Administrative (non-public assumptions)	% of Net Revenue	ross Margin	COGS via Acquisition Royalty to Biosafe 8% \$	COGS-Biosafe Products \$	Revenue via Acquisition Total Revenue	Internet	New Development	Rapid Allergy	Anemia Weter		PSA		Product Revenue: Cholestestol Panel \$	INTERNAL OS
29% INTER	277,738 462,896	740,634	12,000	728,534 46%	200 004	46%	728,634			10,000	15 828		5,540		31,657	umptions)	49%	781,659	126,627 \$	674,552 \$	1,582,838	125,88/	 	ļ		\$50,300 \$	357,000 \$		277,200 \$	2005 (as if)
)% 23% INTERNAL USE ONLY	366,061 610,102	976,163	ŧ	37%	220,000	45%	1,196,163	5,000	26,430	11,965	26,430	5,500	25,000	25,000	52,860 90.000		56%	1,474,348	211,439 \$	957,206 \$ - \$	2,642,994	455,289		t		437.238 \$	541,8/5 \$		450,450 \$	2006
20%	1,021,035 1,701,725	2,722,760	59,730	32%	265,000	35%	2,928,030	45,000	334,043	78,083	83.511	75,000 30,000	128,979	120,000	167,022 570,000		55%	4,559,667	86	3,123,325 \$ - \$	8,351,078	805,123	,	1,276,800		700	1,083,750 \$ 601,530 \$			2007
24%	1,951,207 3,252,011	5,203,218	12,358	38%	315,000 5 100 860	40%	5,505,860	3 185 318	544,186	120,627	136,046	81,000 49,000	161,366	120,000	272,093 650,000)	57%	7,691,178	ŀ	4,825,089 \$ - \$	13,604,638	1,038,146	1,8/1,250	2,394,000			\$ 000,000 \$ 000,000		1,617,000 \$	2008
25 % 4/28	2,641,973 4,403,288	7,045,261	29,885	39%	370,000	41%	7,385,376	2 722 708	717,173	159,672	179,293	87,480 45,000	190,503	180,000	358,587 730,000		56%	10,108,084	1,434,346	6,386,897	17,929,327	1,240,777	3,742,500	2,992,500	627,750	2,761,500	932 400	1,827,900	1,886,500	2009
₆ 4/28/200811:04 AM																														

Retail Newco

Newco Retail Confidential Confidential Projected Balance Sheet INTERNAL USE ONLY

Annual 2005

Annual 2009

	Total Liabilitie			Shareholders			Liabilities		Assets
	s and Stockholders Equity	Total Stockholders Equity	Beg Retained Earnings Current Period Income(Loss) Ending Retained Earnings	Equity Common Stock	Other Long Term Liabilities Notes Payable - Long Term Total Liabilities	Total Current Liabilities	A/P Trade Payroll and Payroll Taxes Compliance Accrual	Property, Equip & Cap Devl Costs, net Goodwilt Product Licenses Total Assets	Cash Accounts Receivable (net of allowance) Inventories Prepaid Expenses Refundable Deposits Total Current Assets
	0	0	0	0	0	0		0	0
	12,354,063	12,110,102	610,102 610,102	11,500,000	0 243,961	243,961	113,961 100,000 30,000	80,000 4,000,000 4,800,000 12,354,063	2,986,492 377,571 100,000 10,000 3,474,063
ı	11,660,907	13,811,826	610,102 1,701,725 2,311,826	11,500,000	(2,700,000) (2,150,920)	549,080	349,080 140,000 60,000	80,000 4,000,000 5,560,000 11,660,907	617,895 1,193,011 200,000 10,000 2,020,907
	14,072,750	17,063,838	2,311,826 3,252,011 5,563,838	11,500,000	(3,750,000) (2,991,088)	758,912	518,912 150,000 90,000	95,000 4,000,000 6,280,000 14,072,750	1,494,230 1,943,520 250,000 10,000 3,697,750
•	19,874,668	21,467,125	5,563,838 4,403,288 9,967,125	11,500,000	(2,550,000) (1,592,457)	957,543	677,543 160,000 120,000	120,000 4,000,000 6,960,000 19,874,668	3,823,336 2,561,332 2,400,000 10,000 8,794,668
	•	12,354,063 11,660,907 14,072,750	Equity 0 12,110,102 13,811,826 17,063,838 0 12,354,063 11,660,907 14,072,750	gs 0 610,102 2,311,826 120,102 1,701,725 3,252,011 e(Loss) 0 610,102 2,311,826 5,563,838 0 12,110,102 13,811,826 17,063,838 2 0 12,354,063 11,660,907 14,072,750 1	9s 0 11,500,000 11,500,000 1 1	Other Long Term Liabilities 0 (2,700,000) (3,750,000) Notes Payable - Long Term 0 243,961 (2,150,920) (2,991,088) Total Liabilities 0 11,500,000 11,500,000 11,500,000 11,500,000 Common Stock 0 11,500,000 11,500,000 11,500,000 11,500,000 Beg Retained Earnings 0 610,102 2,311,826 2,311,826 Current Period Income(Loss) 0 610,102 1,701,725 3,252,011 Ending Retained Earnings 0 610,102 2,311,826 5,563,838 Total Stockholders Equity 0 12,110,102 13,811,826 17,063,838 Stockholders Equity 0 12,354,063 11,660,907 14,072,750	Total Current Liabilities 0 243,961 549,080 758,912 Other Long Term Liabilities 0 (2,700,000) (3,750,000) Notes Payable - Long Term Total Liabilities 0 243,961 (2,150,920) (3,750,000) Common Stock 0 11,500,000 11,500,000 11,500,000 11,500,000 Beg Retained Earnings 0 610,102 1,701,725 3,252,011 Current Period Income(Loss) 0 610,102 1,701,725 3,252,011 Ending Retained Earnings 0 610,102 2,311,826 5,563,838 Total Stockholders Equity 0 12,110,102 13,811,826 17,063,838 Stockholders Equity 0 12,354,063 11,560,907 14,072,750	A/P Trade 113,961 349,080 518,912 Payroll and Payroll Taxes 100,000 140,000 150,000 Compliance Accruel 30,000 80,000 90,000 Notes Payable - Current 0 243,961 549,080 758,912 Other Long Term Liabilities 0 243,961 (2,700,000) (3,750,000) Notes Payable - Long Term 0 243,961 (2,700,000) (3,750,000) Total Liabilities 0 11,500,000 11,500,000 11,500,000 Common Slock 0 0 610,102 2,311,826 2,391,088) Current Period Income(Loss) 0 610,102 1,701,725 3,252,011 Current Period Income(Loss) 0 610,102 2,311,826 5,563,838 Total Stockholders Equity 0 12,10,102 13,811,826 17,083,838 Total Stockholders Equity 0 12,354,063 11,680,907 14,072,750	Property, Equip & Cap Devl Costs, net Goodwill. Licenses 0 80,000 40,000,000 4,000,000 4,000,000 4,000,000 4,000,000 4,000,000 6,280,000 Foldout Licenses 0 4,000,000 4,000,000 4,000,000 6,280,000 6,280,000 6,280,000 6,280,000 6,000 7,000 0,000 1,000 1,000 0,000 1,

	Case 1:07-cv-11135-JSR Document 24-22										nent 24-22 Filed 05/08/2008							
Confidential				Projected Capitalization Table					Projected Long Ten		Ending Cash and Re	Increase other long term liability Issuance of common stock, net	Goodwill purchase Issue of Note Payable for License Repayment of Note Payable	Depreciation/Amortization Net PPE decrease (increa	Change in working capital (less cash): Current assets Current liabilities	Net income (loss)	Beg. Cash and Rese	Newco Retail Projected Statement of Cash Flow
2,500,000 @ \$ 5,000,000 @ \$ 1,500,000 @ \$ 500,000 @ \$ 2,666,666 \$ Ending \$ Value at Issued Price	Beginning \$ Value at Issued Price Shares Issued During Period - \$	Beginning Shares Issued/Outstanding Shares Issued During Period - # Ending Share Count			License Amort years 25		Fixed Assets		Projected Long Term Asset/Liability Work Schedule INTERNAL USE ONLY Confidential Eiged Assets Beginning Ba		Depreciation/Amortization Net PPE decrease (increase) including capitalized R 8 Goodwill purchase Issue of Note Payable for License Repayment of Note Payable Increase other long term liability Issuance of common stock, net of fees Issuance of common stock for Future Development			Depreciation/Amortization Net PPE decrease (increase) including capitalized R & D	oital (less cash):		Beg. Cash and Reserve for Future Development	
\$ 1.00 \$ 1.00 \$ - \$ 1.00 \$ 1.50 ued Price	sued Price ^p eriod - \$	Jeriod - #	ed/Outstanding	INTERNAL USE ONLY	Ending Balance	Beg. Balance Amortization	Ending Balance	Beginning Balance Depreciation/Amort. Purchases/Cap R&D	Schedule Confidential		opment			lized R & D			ment	Confidential
INTERNAL USE (0		Annua 2005	0	0 0	0	0	Annual 2005	0	The state of the s	0		0	0 0			Annua 2005
2,500,000 5,000,000 - 500,000 12,000,000 12,000,000	0	12,166,666	12 166 666	Annual 2006.	4,800,000	0 (200,000) 5,000,000	80,000	(20,000) (100,000	Annual 2006		2,986,492	11,500,000	(4,000,000) 2,500,000 (2,500,000)	220,000 (5,100,000)	(487,571) 243,961	610,102	0	Annual 2006
12,000,000	12,000,000	12,166,666	12,166,666	Annual 2007	5,560,000	4,800,000 (240,000) 1,000,000	80,000	80,000 (25,000) 25,000	Annual 2007	0	617,895	0	(2,700,000)	265,000 (1,025,000)	(915,441) 305,119	1,701,725	2,986,492	Annual 2007
12,000,000	12,000,000	12,166,666	12,166,666	Annual 2008	6,280,000	5,560,000 (280,000) 1,000,000	95,000	80,000 (35,000) 50,000	Annual 2008	0	1,494,230	0	(1,050,000)	315,000 (1,050,000)	(800,509) 209,832	3,252,011	617,895	Annual 2008
4/28/200811:04 AM 12,000,000	12,000,000	12,166,666	12,166,666	Annual 2009	6,960,000	6,280,000 (320,000) 1,000,000	120,000	95,000 (50,000) 75,000	Annual 2009	0	3,823,336	0	2,000,000 (800,000)	370,000 (1,075,000)	(2,767,813) 198,631	4,403,288	1,494,230	Annual 2009

	Case 1	:07-		35-JSR		ıment 24		Filed 05		ge 5 of 7	
Wholesale price Gross Margin %	Cost of Goods Sold: Unit COGS: Kits (& outbound shipping) Lab Processing (if any & net of non-compliance) Outsource Vendor Markup Total Unit Cost		Unit Price Revenue COGS	Stores Kits per Store/year	Unit Price Revenue COGS	Stores Kits per Storelyear	Unit Price Revenue COGS	Stores Kits per Store/year	Stores Kils per Store/year Unit Price Revenue	Stores Stores Kits per Store/year Unit Price Revenue COGS	
↔	on-compliance) 10%		2009 \$ \$	2009	2008 \$ 2008 \$	2008	2007 \$	2007	2006 2006 \$ \$	2005 \$ 2005 \$	
19.25 \$ 64%	2.00 4.22 0.62 6.84	Cholesterol Panel	19.25 \$ 1,886,500 \$ 670,516 \$	14,000 7 98,000	19.25 \$ 1,617,000 \$ 574,728 \$	12,000 7 84,000	19.25 \$ 1,145,375 \$ 407,099 \$	8,500 7 59,500	3,900 6 23,400 19.25 \$ 450,450 \$	2,400 6 14,400 19.25 \$ 277,200 \$ 98,525 \$	Cholestestol T-
20.31 \$ 60%	3.95 3.40 0.73 8.08	HST	20.31 \$ 1,827,900 \$ 727,403 \$	15,000 6 90,000	20.31 \$ 1,706,040 \$ 678,909 \$	14,000 6 84,000	20.31 \$ 1,218.600 \$ 484,935 \$	10,000 6 60,000	5,800 4 23,200 20,31 \$ 20,31 \$ 471,192 \$ 187,508 \$	4,200 3 12,600 20,31 \$ 255,906 \$ 101,836 \$	TSH
21.26 \$ 64%	1.20 5.87 0.69 7.55	PSA He	21.25 \$ 1,912,500 \$ 679,635 \$	15,000 6 90,000	21.25 \$ 1,785,000 \$ 634,326 \$	14,000 6 84,000	21.25 \$ 1,083,750 \$ 385,127 \$	8,500 6 51,000	5,100 5 25,500 21.25 \$ 541,875 \$	4,200 4 16,800 21.25 357,000 \$ 126,865 \$	Send-in PSA He
12.95 \$ 56%	1.49 3.65 0.51 5.65	Hemoglobin A1c N	12.95 \$ 932,400 \$ 407,088 \$	12,000 6 72,000	12.95 \$ 699,300 \$ 305,316 \$	9,000 6 54,000	12.95 \$ 691,530 \$ 301,924 \$	8,900 6 53,400	1,200 6,000 12,95 \$ 77,700 \$	200 4 800 12.95 \$ 10,360 \$ 4,523 \$	Hemoglobin Di
9.21 \$ 43%	1.95 2.85 0.46 5.28	Disease Management	9.21 \$ 2,761,500 \$ 1,584,000 \$	10,000 30 300,000	9.21 \$ 1,656,900 \$ 950,400 \$	4,500 40 180,000	9.21 \$ 1,288,700 \$ 739,200 \$	3,500 40 140,000	1,900 25 47,500 9.21 \$ 437,238 \$ 250,800 \$	750 80 60,000 9.21 \$ 552,300 \$	Disease Mangt An Kits
13.95 \$ 80%	2.50 0.25 2.75	Anemia	13.95 \$ 627,750 \$ 123,750 \$	15,000 3 45,000	13.95 \$ 837,000 \$ 165,000 \$	15,000 4 60,000	13.95 \$ 781,200 \$ 154,000 \$	14,000 4 56,000	2,500 6 15,000 13,95 209,250 \$	100 3 300 13.95 4,185 825 8	Anemia Meter
19.95 \$ 63%	6.79 0.68 7.47	Rapid Allergy	19.95 \$ 2,992,500 \$ 1,120,350 \$		2,394,000 \$ 896,280 \$	15,000 8 120,000	19.95 \$ 1,276,800 \$ 478,016 \$	1	· · ·	40-50	Rapid tests Rapid Allergy
16.85 67%	5.00 0.50 5.50	New Development	24.95 3,742,500 \$ 825,000 \$		24.95 1,871,250 \$ 412,500 \$	7,500 10 75,000	24.95			ज क	Total New Development
			16,683,550 6,137,742		12,566,490 4,617,459		7,485,955 2,950,300		2,187,705 866,148	1,456,951 649,375	[8]

Newco Retail **Employee Listing**

Position	2005	2006	2007	2008
President		200,000	200,000	200,000
Chief Accountant		75,000	75,000	75,000
VP Sales		135,000	135,000	135,000
Brand Manager(s)		80,000	80,000	160,000
Sales Assistant		45,000	45,000	45,000
Admin		35,000	35,000	35,000
Total	- '	570,000	570,000	650,000

2009	
200,000	
75,000	
135,000	
240,000	
45,000	
35,000	
730 000	